Emily Clarke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emily Clarke has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
Raj Patel
Royal South Hants Hospital, Southampton, UK
8 shared publications- Angela Obasi
Affiliation Department of International Public Health, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
5 shared publications Elizabeth Foley
Royal South Hants Hospital, Southampton, UK
5 shared publicationsRajul Patel
Department of Sexual Health, Solent NHS Trust, Southampton, UK
4 shared publicationsBelinder Nahal
University of Liverpool, Liverpool, UK
3 shared publicationsBethany Harrison
Axess Sexual Health, Liverpool University Hospitals NHS Foundation Trust Royal Liverpool University Hospital Liverpool UK
3 shared publications
Latest Publications
- 8 May 2026
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (9) , 1035-1040
An evaluation of the clinical impact of serological testing for herpes simplex virus in a regional UK sexual health service
UK guidelines recommend herpes simplex virus (HSV) serology in limited situations, including distinguishing recent from established infections, excluding HSV in recurrent PCR negative lesions, identifying serodiscordant partners, or determining if a pregnant person with known HSV has both types. Challenges with testing include cost, delayed results, and interpretation. We aimed to determine whether HSV serology impacted on patient management. All HSV serology results between 04/10/2021 and 12/12/2025 at our large sexual health service in northwest England were reviewed and matched with HSV PCR results, and demographic and clinical data from patient records. 77 patients had HSV serology of whom 74 (96%) were female and 70 (91%) pregnant. Three (4%) tests were performed to exclude HSV as a cause of recurrent PCR negative ulceration, of which 2 were negative and 1 positive for HSV-1. Twelve (16%) tests were undertaken to identify serodiscordance with partners in pregnancy, with 1 demonstrating serodiscordance. Among pregnant patients, 34 (44%) had testing to identify new infection at first presentation with genital lesions, and 24 (31%) to identify whether both HSV types were present in a patient with known previous infection. Three (4%) patients had serological testing outside of guidelines. Serological testing influenced clinical management for 63 (82%) patients including 1/3 (33%) with recurrent PCR negative lesions, 12/12 (100%) of clinically discordant couples, 27/34 (79%) pregnant patients having serology to differentiate new from established infection on first presentation with lesions, 23/24 (96%) pregnant patients with known genital HSV having serology to determine whether they had antibodies to both HSV types, and 0/3 (0%) patients tested outside of UK guidelines. Despite challenges associated with performing and interpreting HSV serology, clinical management, especially pregnancy decisions, was impacted in the majority of cases. This underscores the necessity for streamlined protocols that facilitate testing as recommended in guidelines.
- 8 May 2026
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (9) , 1035-1040
An evaluation of the clinical impact of serological testing for herpes simplex virus in a regional UK sexual health service
UK guidelines recommend herpes simplex virus (HSV) serology in limited situations, including distinguishing recent from established infections, excluding HSV in recurrent PCR negative lesions, identifying serodiscordant partners, or determining if a pregnant person with known HSV has both types. Challenges with testing include cost, delayed results, and interpretation. We aimed to determine whether HSV serology impacted on patient management. All HSV serology results between 04/10/2021 and 12/12/2025 at our large sexual health service in northwest England were reviewed and matched with HSV PCR results, and demographic and clinical data from patient records. 77 patients had HSV serology of whom 74 (96%) were female and 70 (91%) pregnant. Three (4%) tests were performed to exclude HSV as a cause of recurrent PCR negative ulceration, of which 2 were negative and 1 positive for HSV-1. Twelve (16%) tests were undertaken to identify serodiscordance with partners in pregnancy, with 1 demonstrating serodiscordance. Among pregnant patients, 34 (44%) had testing to identify new infection at first presentation with genital lesions, and 24 (31%) to identify whether both HSV types were present in a patient with known previous infection. Three (4%) patients had serological testing outside of guidelines. Serological testing influenced clinical management for 63 (82%) patients including 1/3 (33%) with recurrent PCR negative lesions, 12/12 (100%) of clinically discordant couples, 27/34 (79%) pregnant patients having serology to differentiate new from established infection on first presentation with lesions, 23/24 (96%) pregnant patients with known genital HSV having serology to determine whether they had antibodies to both HSV types, and 0/3 (0%) patients tested outside of UK guidelines. Despite challenges associated with performing and interpreting HSV serology, clinical management, especially pregnancy decisions, was impacted in the majority of cases. This underscores the necessity for streamlined protocols that facilitate testing as recommended in guidelines.
- 17 March 2026
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (7) , 794-797
Fracture risk assessment in patients prescribed pre-exposure prophylaxis for HIV: An audit and comparative evaluation of screening tools
Background: Tenofovir disoproxil, a component of most pre-exposure prophylaxis for HIV (PrEP), is associated with reduced bone mineral density. UK guidelines recommend assessing fracture risk for PrEP users aged over 50 years, and in 2025 QFracture joined FRAX as a suggested screening tool. Awareness of fracture risk supports decision making including the need for bone mineral density measurement or use of tenofovir alafenamide-based PrEP. We audited staff adherence to assessment and characterised the clinical impact, including any effect of screening tool choice. Methods: This study reviewed the patient records of PrEP users at nine sexual health services in northwest England during January-April 2025 who met UK guideline criteria for osteoporosis risk assessment. FRAX and QFracture were calculated for each patient and used to determine clinical outcome. Results: Fracture risk assessment had been completed for 156/220 (71%) eligible patients. 6/15 (40%) indicated dual-energy X-ray absorptiometry (DEXA) scans had been requested. 129/220 (59%) patients had sufficient available data for inclusion in the comparison of FRAX and QFracture outcomes. 10-year major osteoporotic fracture risk was significantly lower using QFracture (1.4%) compared to FRAX (3.5%; p < .001), as was the indication for DEXA scan (QFracture 0.8%, FRAX 11.6%; p < .001). Based on FRAX assessment, three patients were switched to PrEP containing tenofovir alafenamide and two started a bisphosphonate for osteoporosis. Use of QFracture would have missed both patients. Conclusions: Choice of screening tool impacts both estimated fracture risk and clinical outcome. FRAX may be preferable to QFracture due to increased sensitivity and may be more feasible by incorporating fewer variables. Fracture risk assessment in line with national guidelines supports best practice for patient case, and services should therefore audit practice and optimise processes to maximise staff adherence.
- 17 March 2026
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (7) , 794-797
Fracture risk assessment in patients prescribed pre-exposure prophylaxis for HIV: An audit and comparative evaluation of screening tools
Background: Tenofovir disoproxil, a component of most pre-exposure prophylaxis for HIV (PrEP), is associated with reduced bone mineral density. UK guidelines recommend assessing fracture risk for PrEP users aged over 50 years, and in 2025 QFracture joined FRAX as a suggested screening tool. Awareness of fracture risk supports decision making including the need for bone mineral density measurement or use of tenofovir alafenamide-based PrEP. We audited staff adherence to assessment and characterised the clinical impact, including any effect of screening tool choice. Methods: This study reviewed the patient records of PrEP users at nine sexual health services in northwest England during January-April 2025 who met UK guideline criteria for osteoporosis risk assessment. FRAX and QFracture were calculated for each patient and used to determine clinical outcome. Results: Fracture risk assessment had been completed for 156/220 (71%) eligible patients. 6/15 (40%) indicated dual-energy X-ray absorptiometry (DEXA) scans had been requested. 129/220 (59%) patients had sufficient available data for inclusion in the comparison of FRAX and QFracture outcomes. 10-year major osteoporotic fracture risk was significantly lower using QFracture (1.4%) compared to FRAX (3.5%; p < .001), as was the indication for DEXA scan (QFracture 0.8%, FRAX 11.6%; p < .001). Based on FRAX assessment, three patients were switched to PrEP containing tenofovir alafenamide and two started a bisphosphonate for osteoporosis. Use of QFracture would have missed both patients. Conclusions: Choice of screening tool impacts both estimated fracture risk and clinical outcome. FRAX may be preferable to QFracture due to increased sensitivity and may be more feasible by incorporating fewer variables. Fracture risk assessment in line with national guidelines supports best practice for patient case, and services should therefore audit practice and optimise processes to maximise staff adherence.
- 24 January 2026
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (6) , 684-685
Topical aciclovir should not be used in the management of anogenital herpes simplex virus
- 24 January 2026
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 37 (6) , 684-685
Topical aciclovir should not be used in the management of anogenital herpes simplex virus
- 5 November 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (11) , e70115
Disseminated Herpes Simplex Virus in Pregnancy: A Systematic Review of Cases
Background: Disseminated herpes simplex virus (HSV) is more common in pregnancy and has a high mortality and morbidity. It is a rare disease, inconsistently addressed by national guidelines and lacking high‐quality data to guide decision making. Objectives: This systematic review of cases of disseminated HSV in pregnant and postpartum adults aims to determine the clinical features, diagnostic methods, and maternal survival rate with and without aciclovir. Search Strategy: A search of MEDLINE, EMBASE and Google was undertaken. Selection Criteria: Studies were included if they were published in English, were case reports, case series, trials or literature reviews, reported data from people assigned female at birth, and were pregnant or postpartum with a laboratory‐confirmed diagnosis of disseminated HSV. Data Collection and Analysis: Two reviewers independently screened studies, extracted data on participant and intervention characteristics using a standardized Excel template, and assessed risk of bias. Main Results: A total of 114 cases were analyzed from 109 papers (1966–2024). 104 cases (91.2%) reported from high‐income countries. Most patients were in the third trimester ( n = 62, 54.4%) and had HSV‐2 ( n = 58, 66.7%). Clinical features were non‐specific: fever ( n = 99, 86.8%), deranged liver function tests ( n = 81, 71.1%), neuropsychiatric symptoms ( n = 72, 63.2%), gastrointestinal symptoms ( n = 72, 63.2%). Antemortem diagnosis occurred in 89.5% ( n = 102). Maternal survival rate with aciclovir was 0.88 (95% CI: 0.80–0.94) and without was 0.42 (95% CI: 0.25–0.59). Conclusions: A high index of suspicion is required for diagnosis due to non‐specific clinical features. Mandatory reporting and inclusion of disseminated HSV in sepsis guidelines are recommended.
- 5 November 2025
- Published by Wiley in Journal of Obstetrics and Gynaecology Research
- Vol. 51 (11) , e70115
Disseminated Herpes Simplex Virus in Pregnancy: A Systematic Review of Cases
Background: Disseminated herpes simplex virus (HSV) is more common in pregnancy and has a high mortality and morbidity. It is a rare disease, inconsistently addressed by national guidelines and lacking high‐quality data to guide decision making. Objectives: This systematic review of cases of disseminated HSV in pregnant and postpartum adults aims to determine the clinical features, diagnostic methods, and maternal survival rate with and without aciclovir. Search Strategy: A search of MEDLINE, EMBASE and Google was undertaken. Selection Criteria: Studies were included if they were published in English, were case reports, case series, trials or literature reviews, reported data from people assigned female at birth, and were pregnant or postpartum with a laboratory‐confirmed diagnosis of disseminated HSV. Data Collection and Analysis: Two reviewers independently screened studies, extracted data on participant and intervention characteristics using a standardized Excel template, and assessed risk of bias. Main Results: A total of 114 cases were analyzed from 109 papers (1966–2024). 104 cases (91.2%) reported from high‐income countries. Most patients were in the third trimester ( n = 62, 54.4%) and had HSV‐2 ( n = 58, 66.7%). Clinical features were non‐specific: fever ( n = 99, 86.8%), deranged liver function tests ( n = 81, 71.1%), neuropsychiatric symptoms ( n = 72, 63.2%), gastrointestinal symptoms ( n = 72, 63.2%). Antemortem diagnosis occurred in 89.5% ( n = 102). Maternal survival rate with aciclovir was 0.88 (95% CI: 0.80–0.94) and without was 0.42 (95% CI: 0.25–0.59). Conclusions: A high index of suspicion is required for diagnosis due to non‐specific clinical features. Mandatory reporting and inclusion of disseminated HSV in sepsis guidelines are recommended.
- 25 September 2025
- Published by Elsevier in Clinics in Dermatology
- Vol. 44 (1) , 40-47
Herpes simplex virus (update on dermatologic aspects of sexually transmitted disease and human immunodeficiency virus)
- 25 September 2025
- Published by Elsevier in Clinics in Dermatology
- Vol. 44 (1) , 40-47
Herpes simplex virus (update on dermatologic aspects of sexually transmitted disease and human immunodeficiency virus)
- 24 June 2025
- Published by SAGE Publications in International Journal of STD & AIDS
Mycoplasma genitalium treatment strategies in the era of significant macrolide resistance: Findings from a multi-centre audit in Northwest England
Introduction: Azithromycin is first-line for uncomplicated Mycoplasma genitalium (Mgen) treatment in UK and European guidelines, however the rates of azithromycin resistance have increased significantly in recent years leading to higher rates of treatment failure. This study aims to review the disease epidemiology to guide service improvement. Methods: We undertook a retrospective case note review of 1036 persons treated for Mgen over 1067 Mgen-related attendances. We obtained data on demographics, site(s) of infection, antibiotic resistance, treatment regimen received and results of test of cure. Results: 71.1% ( n = 759) patients received the recommended first-line regimen of doxycycline and azithromycin. Moxifloxacin is the recommended first-line management for macrolide-resistant or complicated infection. 15% ( n = 155) patients received moxifloxacin alone as first-line treatment, and 6.9% ( n = 72) patients received doxycycline and moxifloxacin dual therapy. 72.9% ( n = 753) samples were successfully tested for macrolide resistance. Of these, 55.5% ( n = 418) showed macrolide resistance. 20.6% ( n = 7) showed fluoroquinolone resistance. Conclusions: Resistance data show a macrolide resistance rate of 55.5% across our region, and at least 1 in 10 persons were inappropriately screened for Mgen. We propose a multi-pronged approach which includes strict adherence to testing criteria, local resistance testing, resistance-guided management as well as innovative approaches to improve test of cure rates.
- 24 June 2025
- Published by SAGE Publications in International Journal of STD & AIDS
Mycoplasma genitalium treatment strategies in the era of significant macrolide resistance: Findings from a multi-centre audit in Northwest England
Introduction: Azithromycin is first-line for uncomplicated Mycoplasma genitalium (Mgen) treatment in UK and European guidelines, however the rates of azithromycin resistance have increased significantly in recent years leading to higher rates of treatment failure. This study aims to review the disease epidemiology to guide service improvement. Methods: We undertook a retrospective case note review of 1036 persons treated for Mgen over 1067 Mgen-related attendances. We obtained data on demographics, site(s) of infection, antibiotic resistance, treatment regimen received and results of test of cure. Results: 71.1% ( n = 759) patients received the recommended first-line regimen of doxycycline and azithromycin. Moxifloxacin is the recommended first-line management for macrolide-resistant or complicated infection. 15% ( n = 155) patients received moxifloxacin alone as first-line treatment, and 6.9% ( n = 72) patients received doxycycline and moxifloxacin dual therapy. 72.9% ( n = 753) samples were successfully tested for macrolide resistance. Of these, 55.5% ( n = 418) showed macrolide resistance. 20.6% ( n = 7) showed fluoroquinolone resistance. Conclusions: Resistance data show a macrolide resistance rate of 55.5% across our region, and at least 1 in 10 persons were inappropriately screened for Mgen. We propose a multi-pronged approach which includes strict adherence to testing criteria, local resistance testing, resistance-guided management as well as innovative approaches to improve test of cure rates.
- Open Access
- 28 October 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1103-1113
Perspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study
Introduction: The equity-focused Implementing Long-Acting Novel Antiretrovirals study evaluated feasibility, acceptability, appropriateness of delivering on-label 2-monthly cabotegravir and rilpivirine (CAB + RPV) injections for human immunodeficiency virus (HIV)-1 therapy in clinics and community settings. Methods: The study, which mandated inclusive recruitment, was conducted May–December 2022 at 6 UK sites. Injections were delivered in clinic (month [M] 1–6) and in clinic or community setting according to patient choice (M6–12). Surveys were completed at baseline, M4, and M12 using validated measures for feasibility (FIM), acceptability (AIM), and appropriateness (IAM). Primary endpoint: proportion of participants agreeing that the injection and community setting were feasible (FIM ≥4) at M12. Fourteen participants completed interviews at baseline and M12. Results: Community settings offered by sites included: home visits (n = 3), HIV support organizations (n = 2), and community clinic (n = 1). Of 114 participants, 54% were female, 70% racially minoritized, and 40% aged ≥50 years. A total of 27/114 chose to receive injections in community settings. FIM/AIM/IAM scores at M12 were high for the injection (79.0–87.4%) and lower for the community setting (44.2–47.4%) overall. Subgroup analyses indicated differences in scores by gender and ethnicity. Among those who attended the community, FIM/AIM/IAM scores for the community setting at M12 were high (73.1–80.8%). Concerns about stigma, inconvenience, and losing access to trusted clinicians negatively influenced perceptions of receiving injections at community settings, amongst other factors. Conclusions: CAB + RPV injections were considered highly feasible, acceptable, and appropriate; however, few chose community delivery. Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB + RPV delivery in alternative community sites not offered (eg, primary care, pharmacies) is warranted. ClinicalTrials.gov: NCT05294159
- 28 October 2024
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 80 (5) , 1103-1113
Open AccessPerspectives of People With HIV on Implementing Long-acting Cabotegravir Plus Rilpivirine in Clinics and Community Settings in the United Kingdom: Results From the Antisexist, Antiracist, Antiageist Implementing Long-acting Novel Antiretrovirals Study
Introduction: The equity-focused Implementing Long-Acting Novel Antiretrovirals study evaluated feasibility, acceptability, appropriateness of delivering on-label 2-monthly cabotegravir and rilpivirine (CAB + RPV) injections for human immunodeficiency virus (HIV)-1 therapy in clinics and community settings. Methods: The study, which mandated inclusive recruitment, was conducted May–December 2022 at 6 UK sites. Injections were delivered in clinic (month [M] 1–6) and in clinic or community setting according to patient choice (M6–12). Surveys were completed at baseline, M4, and M12 using validated measures for feasibility (FIM), acceptability (AIM), and appropriateness (IAM). Primary endpoint: proportion of participants agreeing that the injection and community setting were feasible (FIM ≥4) at M12. Fourteen participants completed interviews at baseline and M12. Results: Community settings offered by sites included: home visits (n = 3), HIV support organizations (n = 2), and community clinic (n = 1). Of 114 participants, 54% were female, 70% racially minoritized, and 40% aged ≥50 years. A total of 27/114 chose to receive injections in community settings. FIM/AIM/IAM scores at M12 were high for the injection (79.0–87.4%) and lower for the community setting (44.2–47.4%) overall. Subgroup analyses indicated differences in scores by gender and ethnicity. Among those who attended the community, FIM/AIM/IAM scores for the community setting at M12 were high (73.1–80.8%). Concerns about stigma, inconvenience, and losing access to trusted clinicians negatively influenced perceptions of receiving injections at community settings, amongst other factors. Conclusions: CAB + RPV injections were considered highly feasible, acceptable, and appropriate; however, few chose community delivery. Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB + RPV delivery in alternative community sites not offered (eg, primary care, pharmacies) is warranted. ClinicalTrials.gov: NCT05294159
- Open Access
- 7 October 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (2) , 90-105
British Association of Sexual Health and HIV UK national guideline for the management of anogenital herpes, 2024
The guideline provides recommendations on the management of adults with anogenital herpes in the UK. Recommendations include diagnostic tests, management of the primary or first episode of anogenital herpes and recurrences, effectiveness of therapy, prophylaxis, and prevention of transmission between partners, as well as patient centred counselling.
- 7 October 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (2) , 90-105
Open AccessBritish Association of Sexual Health and HIV UK national guideline for the management of anogenital herpes, 2024
The guideline provides recommendations on the management of adults with anogenital herpes in the UK. Recommendations include diagnostic tests, management of the primary or first episode of anogenital herpes and recurrences, effectiveness of therapy, prophylaxis, and prevention of transmission between partners, as well as patient centred counselling.
- 30 September 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (1) , 4-23
Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of herpes simplex virus (HSV) in pregnancy and the neonate (2024 update)
This updated national UK guideline offers recommendations on the management of genital herpes simplex virus (HSV) in mothers and pregnant people during pregnancy and within 4 weeks following birth. It includes recommendations for first episode and recurrent HSV, HSV in preterm pre-labour rupture of membranes and in co-infection with HSV and HIV. Recommendations around management of the neonate are made, on prevention of postnatal transmission, management of breastfeeding, and the management of clinically discordant couples. This guideline is aimed at healthcare professionals working in sexual health clinics, maternity units, and those working on postnatal wards and neonatal units in the UK. However, the principles of the recommendations should be adopted across all services, including community care.
- 30 September 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 36 (1) , 4-23
Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of herpes simplex virus (HSV) in pregnancy and the neonate (2024 update)
This updated national UK guideline offers recommendations on the management of genital herpes simplex virus (HSV) in mothers and pregnant people during pregnancy and within 4 weeks following birth. It includes recommendations for first episode and recurrent HSV, HSV in preterm pre-labour rupture of membranes and in co-infection with HSV and HIV. Recommendations around management of the neonate are made, on prevention of postnatal transmission, management of breastfeeding, and the management of clinically discordant couples. This guideline is aimed at healthcare professionals working in sexual health clinics, maternity units, and those working on postnatal wards and neonatal units in the UK. However, the principles of the recommendations should be adopted across all services, including community care.
- 20 August 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 35 (12) , 997-998
BASHH standards for the management of sexual health in UK prisons
People in prison often experience risk factors that can lead to poor sexual health which is compounded by social deprivation. In response, the British Association for Sexual Health and HIV (BASHH) has published the first national standards in the management of UK prisons, providing recommendations for commissioners, service providers, health care providers and people in prison. Nine standards have been devised which cover aspects of sexual health diagnosis and management, public health measures, and some reproductive health issues. The aim of these standards is to drive improvements in sexual health provision in prisons to ensure access to high quality care that is equitable to that which is provided to the general population.
- 20 August 2024
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 35 (12) , 997-998
BASHH standards for the management of sexual health in UK prisons
People in prison often experience risk factors that can lead to poor sexual health which is compounded by social deprivation. In response, the British Association for Sexual Health and HIV (BASHH) has published the first national standards in the management of UK prisons, providing recommendations for commissioners, service providers, health care providers and people in prison. Nine standards have been devised which cover aspects of sexual health diagnosis and management, public health measures, and some reproductive health issues. The aim of these standards is to drive improvements in sexual health provision in prisons to ensure access to high quality care that is equitable to that which is provided to the general population.